Crossmark

Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review

Crossref DOI link: https://doi.org/10.1186/s12885-024-12271-0

Published Online: 2024-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Yusheng

Pan, Yao

Wan, Jiayu

Gong, Bingxin

Li, Yi

Kan, Xuefeng

Zheng, Chuansheng
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (Nos. 82372069 and 82072041)

Outstanding Youth Science Foundation of Hubei Province, China (2023AFA107)
License Information

Text and Data Mining valid from 2024-04-25

Version of Record valid from 2024-04-25
More Information

Article History

Received: 11 November 2023

Accepted: 16 April 2024

First Online: 25 April 2024

Declarations

:

: Not applicable.

: Not applicable (systematic review and meta-analysis of published data).

: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Document is current

Any future updates will be listed below